𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prospective Randomized Trial of Two Different Immunoadsorbers in Severe Systemic Lupus Erythematosus

✍ Scribed by Markus Gaubitz; Matthias Seidel; Sascha Kummer; Heiko Schotte; Andreas Perniok; Wolfram Domschke; Matthias Schneider

Book ID
115621594
Publisher
Elsevier Science
Year
1998
Tongue
English
Weight
198 KB
Volume
11
Category
Article
ISSN
0896-8411

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Efficacy and safety of rituximab in mode
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
✍ Joan T. Merrill; C. Michael Neuwelt; Daniel J. Wallace; Joseph C. Shanahan; Kevi πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 499 KB πŸ‘ 2 views

## Abstract ## Objective B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in p

A randomized clinical trial of a psychoe
A randomized clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus
✍ Elizabeth W. Karlson; Matthew H. Liang; Holley Eaton; Jie Huang; Lisa Fitzgerald πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 2 views

## Abstract ## Objective In a cross‐sectional study, we previously identified 2 potentially modifiable risk factors for adverse outcomes in systemic lupus erythematosus (SLE): self‐efficacy and social support. The goal of this study was to evaluate in a randomized controlled trial a theory‐based i